This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2022 Jul;17(7):862-864.

doi: 10.1016/j.jtho.2022.05.005.

Somatic BAP1 Loss as a Predictive Biomarker of Overall Survival in Patients With Malignant Pleural Mesothelioma Treated With Chemotherapy

Azam Ghafoor¹, Raffit Hassan²

Affiliations

Affiliations

¹ Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
² Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. Electronic address: hassanr@mail.nih.gov.

PMID: 35750452
DOI: 10.1016/j.jtho.2022.05.005

Free article

Editorial

Somatic BAP1 Loss as a Predictive Biomarker of Overall Survival in Patients With Malignant Pleural Mesothelioma Treated With Chemotherapy

Azam Ghafoor et al. J Thorac Oncol. 2022 Jul.

Free article

. 2022 Jul;17(7):862-864.

doi: 10.1016/j.jtho.2022.05.005.

Authors

Azam Ghafoor¹, Raffit Hassan²

Affiliations

¹ Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
² Thoracic and GI Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. Electronic address: hassanr@mail.nih.gov.

PMID: 35750452
DOI: 10.1016/j.jtho.2022.05.005

No abstract available

PubMed Disclaimer

Comment on

BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum and Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma: A Validation Study.
Louw A, Panou V, Szejniuk WM, Meristoudis C, Chai SM, van Vliet C, Lee YCG, Dick IM, Firth T, Lynggaard LA, Asghari AB, Vyberg M, Hansen J, Creaney J, Røe OD. Louw A, et al. J Thorac Oncol. 2022 Jul;17(7):921-930. doi: 10.1016/j.jtho.2022.04.008. Epub 2022 Apr 27. J Thorac Oncol. 2022. PMID: 35489694

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information